the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Guide to Good Clinical Practice, 3rd Edition

Published by Drug & Market Development Publications Contact us : +1-860-674-8796
Published 2007/09 Content info 468 pages
Product code DM56526
Price From  US $ 995 Order/Price list
US $ 995 PDF by E-mail (Single User License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Table of Contents

Chapter 1: Executive Summary

Chapter 2: Introduction

  • The Phases of Clinical Study
  • Clinical Trials Design and Analysis
  • Corporate Implications of Non-compliance with GCP

Chapter 3: International Regulations Governing GCP

  • History of GCP Legislation
  • Current Regulations
    • U.S.A
    • Canada
    • Japan

Chapter 4: The Elements of GCP Compliance

  • Introduction
  • The Principles of ICH GCP
  • Standard Operating Procedures as Tools for GCP Compliance

Chapter 5: The Sponsor?Duties and Responsibilities

  • General Responsibilities of the Sponsor
  • Contract Research Organization (CRO)?312.52
    • Medical Expertise
    • Trial Design and Management
    • Investigator Selection and Assignment of Duties and Functions
    • Compensation and Financing
    • Submissions to Regulatory Authorities
    • Investigator' s Brochure (IB)
    • Investigational Drug Products
    • Record Access
    • Safety Information and Adverse Drug Effects Reporting
    • Annual Reports
    • Study Monitoring
    • Non-compliance
    • Premature Trial Termination or Suspension
    • Trial Reports
    • Regional Variations of Sponsor' s GCP Responsibilities

Chapter 6: The Clinical Investigator?Duties and Responsibilities

  • Qualifications and Agreements
    • Communication with IRB
    • Investigational Drug Products
    • Informed Consent
    • Records and Reports
    • Progress Reports
    • Safety Reports
    • Final Investigator' s Report
  • Common Technical Document Requirements
    • Premature Trial Termination or Suspension
    • Regional Variations of Investigator' s GCP Responsibilities

Chapter 7: The Institutional Review Board/Independent Ethics Committee (IRB/IEC)

  • Responsibilities
  • Composition and Operations
  • Review Procedures
  • Subject Recruitment Advertising
  • Informed Consent Form
  • DHHS Regulations
  • Records
  • Regional Variations of IRB Duties and Responsibilities

Chapter 8: The Investigator' s Brochure

  • General Considerations
    • Brochure Contents

Chapter 9: The Clinical Trial Protocol

  • General Information
  • Background Information
  • Study Purpose and Objectives
  • Study Design
  • Selection, Withdrawal, and Treatment of Subjects
  • Assessments of Efficacy and Safety
  • Statistical Analyses
  • Other Provisions
  • Data Handling and Record Keeping?Computerized Systems
  • Protocol Amendments

Chapter 10: Essential Documents for Trial Conduct

  • Introduction
  • Before the Trial
  • During the Clinical Phase
  • After Completion or Termination

Chapter 11: Internal and External Monitoring and Inspections

  • Sponsor' s Monitoring
    • Selection and Qualification of Monitors
    • Extent and Nature of Monitoring
    • Monitor' s Responsibilities
      • Pre-investigation Visits
      • Visits During the Study
      • Study Follow-up Visits
    • Monitoring Reports
  • Sponsor' s Study Audit
    • Purpose
    • Selection and Qualification of Auditors
    • Auditing Procedures
  • Regulatory Inspections
    • Sponsor and Monitor Inspections
    • IRB Inspections
    • Investigator/site Inspections
  • How to Cope with Audits and Inspections
  • Before the Event
    • During the Inspection
    • After the Event
    • Regulatory follow-up Action and Sanctions

Chapter 12: Checklists and Forms for Monitoring and Audits

Chapter 13: References and Further Reading

  • Access to Regulatory Documents
  • Guidelines to GCP
  • Advisory Bodies, Publications and Web Sites
  • Clinical Trial Management Companies and Consultants

Chapter 14: Text of Regulations and Guidelines

  • U.S.A. Code of Federal Regulations, Title 21
  • Guidance for Industry Computerized Systems Used in Clinical Investigations
  • Canada
  • Japan
  • New European Directives
  • ICH Consolidated Guideline
  • The Declaration of Helsinki

TABLE OF EXHIBITS

  • Exhibit 2.1 Stages of Drug Development
  • Exhibit 2.2 Drug Clinical Trial Phases
  • Exhibit 2.3 Classification of Clinical Studies by Objectives
  • Exhibit 3.1 Member Nations of the European Union
  • Exhibit 3.2 Comparison of GCP Regulations and ICH Guidelines
  • Exhibit 3.3 Consolidated Guideline, as Adopted by the Three ICH Regions
  • Exhibit 4.1 The Clinical Trial Triangle
  • Exhibit 4.2 SOP Form for a Laboratory Test
  • Exhibit 4.3 SOP Form for a Procedure
  • Exhibit 4.4 Minimum List of SOPs for a Clinical Study
  • Exhibit 6.1 Diagram of the CTD
  • Exhibit 6.2 Contents of CTD Clinical Summary Sections in Module 2
  • Exhibit 6.3 Content of CTD Efficacy Section, Module 5
  • Exhibit 8.1 Contents of an Investigator' s Brochure
  • Exhibit 10.1 Essential Documents Required Before the Trial Starts
  • Exhibit 10.2 Documents Generated During the Trial
  • Exhibit 10.3 Documents to be Added After the Trial
  • Exhibit 12.1 IRB Checklist
  • Exhibit 12.2 Monitoring Visit Report
  • Exhibit 12.3 CRF Review Form
  • Exhibit 12.4 Source Data Verification Form
  • Exhibit 12.5 Clinical Site Regulatory Binder Check List
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.